Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib With Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma
NCT05232552Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05232552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232552.